NeuroVision Imaging
NeuroVision Imaging is a Sacramento-based digital diagnostics company building the BrainHealth Platform—an integrated system combining Afina AI retinal imaging, Duritect blood-based biomarkers, and the BrainHealth Clinic telehealth cognitive-care platform—to enable earlier detection and longitudinal management of Alzheimer's, Parkinson's, and ALS for primary care providers, patients, and pharmaceutical research partners across the United States.
- Company typePrivate
- Founded2010
- HeadquartersSacramento, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingSoftware
What NeuroVision Imaging does
NeuroVision Imaging, Inc. is a Sacramento-based, venture-backed developer of integrated digital diagnostics and care-delivery infrastructure for neurodegenerative diseases (Alzheimer's, Parkinson's, and ALS). The company operates a three-module platform branded as the BrainHealth Platform: BrainHealth Clinic™, a national US telehealth cognitive-care platform that manages the full patient journey from first concern through assessment, imaging, biomarker testing, neurology consultation, and longitudinal engagement; Afina™, a cloud-based AI retinal imaging pathway that analyzes non-invasive scans in minutes to identify retinal signatures associated with neurodegenerative disease and to support treatment safety monitoring; and Duritect™, a blood-based autoantibody biomarker diagnostic platform acquired in May 2026 through the purchase of Durin Life Sciences. Several Afina and Duritect components remain investigational and are not yet FDA-cleared or approved.
The company serves three primary customer segments: healthcare providers and health systems (primary care physicians, neurology practices, and integrated delivery networks seeking to embed cognitive screening and specialty referral into routine workflows); patients and caregivers concerned about cognitive decline who self-initiate evaluation through the BrainHealth.net portal; and academic medical centers and pharmaceutical research partners (Cedars-Sinai, UCLA Health, Emory, University of Pennsylvania, University of Cambridge, University of Oxford, Janssen, Lilly, Alnylam, Labcorp, AIBL) collaborating on validation and clinical studies. Its revenue model combines usage-based diagnostic testing (Afina retinal imaging and Duritect blood biomarkers), managed-services and subscription revenue from telehealth cognitive care via BrainHealth Clinic, and enterprise contracts with health systems and primary care networks.
The business is led by CEO Steven Verdooner (30+ years in ophthalmology/neurology medical devices; co-founder/former CEO of Ophthalmic Imaging Systems) and is backed by Wildcat Capital Management, Tiny Orange Capital, Gaston Capital Partners, JJ Development, VSP, Gates Ventures, Labcorp, and the Alzheimer's Drug Discovery Foundation. The board includes Ric Edelman, Len Potter, Mark Selna, Roy Twyman, René Chaze, and Glenn Walthall, combining expertise in financial services scale, pharmaceutical R&D, health-system leadership, and venture capital.
NeuroVision Imaging firmographics
Firmographics- Name
- NeuroVision Imaging
- Legal name
- NeuroVision Imaging, Inc.
- Website
- https://neurovision.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeuroVision Imaging is a Sacramento-based digital diagnostics company building the BrainHealth Platform—an integrated system combining Afina AI retinal imaging, Duritect blood-based biomarkers, and the BrainHealth Clinic telehealth cognitive-care platform—to enable earlier detection and longitudinal management of Alzheimer's, Parkinson's, and ALS for primary care providers, patients, and pharmaceutical research partners across the United States.
- Ownership category
- akta.pro rank
NeuroVision Imaging industry classification
Industry- Product category
- Neurodegenerative Disease Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurology Telemedicine Platforms (HLALAGAC)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where NeuroVision Imaging is headquartered
LocationHeadquarters
- HQ city
- Sacramento
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuroVision Imaging business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Telehealth Cognitive Care Services: Revenue from BrainHealth Clinic telehealth cognitive assessments, neurology consultations, imaging and biomarker testing, and longitudinal patient management. Likely recurring subscription or per-engagement model.
- Diagnostic Testing (Afina retinal imaging & Duritect blood biomarkers): Revenue from delivery of retinal imaging and blood-based biomarker diagnostic tests for neurodegenerative disease detection and treatment safety monitoring (certain components investigational, not yet FDA-cleared).
- Enterprise / Health System Partnerships: Revenue from enterprise deployments with primary care networks and health systems integrating NeuroVision's diagnostic infrastructure into clinical workflows.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Pricing not publicly disclosed; certain components are investigational and not yet FDA-cleared or approved. |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
NeuroVision Imaging product offering
Product offeringCore offering
NeuroVision Imaging develops and operates an integrated multi-modal diagnostic platform for neurodegenerative diseases, combining cloud-based AI retinal imaging (Afina™), blood-based autoantibody biomarker diagnostics (Duritect™), and a national telehealth cognitive care delivery platform (BrainHealth Clinic™ / BrainHealth.net). The platform connects primary care identification, biomarker interpretation, neurology consultation, and longitudinal patient management across the cognitive care journey.
Product overview
NeuroVision Imaging offers an integrated platform-plus-modules architecture branded as the BrainHealth Platform, which combines three named offerings to close key gaps in the cognitive care journey: BrainHealth Clinic™ (a comprehensive cognitive care telehealth platform covering assessment, imaging and biomarker testing, neurology access, and longitudinal engagement), Afina™ Retinal Imaging (a cloud-based AI retinal imaging pathway that identifies retinal signatures associated with neurodegenerative disease and supports treatment safety monitoring), and Duritect™ (a blood-based autoantibody biomarker diagnostics platform, developed by Durin Life Sciences and acquired by NeuroVision, supporting earlier detection and longitudinal monitoring of Alzheimer's, Parkinson's, and ALS). Together these modules connect primary-care access, multimodal detection (cognition, biomarkers, and imaging), and scalable telehealth delivery across the patient journey.
Differentiator
Problem solved
Functional benefit
Brands
- BrainHealth Clinic™: Comprehensive cognitive care telehealth platform managing the full patient journey for cognitive disease — assessment, imaging and biomarker testing, neurology access, patient/caregiver engagement, and longitudinal management. Associated with the BrainHealth.net digital health platform.
- Afina™
- Duritect™
Products and services
- BrainHealth Clinic™ A comprehensive cognitive care telehealth platform that manages the full patient journey from first concern through ongoing treatment and support, including cognitive assessment, imaging and biomarker testing, neurology consultation, and longitudinal patient and caregiver engagement. Designed for patients and caregivers concerned about cognitive decline.
- Afina™ Retinal Imaging A cloud-based AI imaging pathway designed to identify retinal signatures associated with neurodegenerative disease and treatment safety monitoring. Performs non-invasive scans in minutes with AI-enabled analysis for disease signatures. For healthcare providers, clinical researchers, and patients.
- Duritect™ A blood-based autoantibody biomarker diagnostics platform supporting earlier detection and longitudinal monitoring of neurodegenerative diseases, including Alzheimer's, Parkinson's disease, and ALS. Designed for real-world clinical deployment. For healthcare providers and clinical researchers.
- BrainHealth Platform The integrated umbrella platform combining BrainHealth Clinic™ (telehealth care), Afina™ Retinal Imaging (retinal imaging), and Duritect™ (blood biomarkers) into a single continuum from first concern to clinical action for cognitive disease detection and management.
Quantifiable outcome
- 75% of dementia cases are undiagnosed or diagnosed only after significant irreversible decline
- +2 more outcomes
Companies that use NeuroVision Imaging
Customer profileSegments3 records
Ideal customer profiles3 records
NeuroVision Imaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
NeuroVision Imaging partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
NeuroVision Imaging competitors and assessment
Company assessmentDirect peers
- C2N Diagnostics: Developer of the PrecivityAD blood-based biomarker test for Alzheimer's disease. Direct peer because C2N operates in the same neurodegenerative-diagnostic category with a similar blood-biomarker-plus-clinical-workflow thesis competing for PCP and neurology adoption.
- RetiSpec: AI retinal imaging company developing non-invasive eye-based biomarkers for Alzheimer's and other neurodegenerative diseases. Direct peer — directly comparable technology pathway to NeuroVision's Afina retinal imaging modality.
- Quanterix: Simoa-platform company enabling ultra-sensitive blood-based biomarker detection for neurodegenerative disease research and clinical use. Direct peer in the blood-biomarker detection category that complements NeuroVision's Duritect assays.
Emerging players
- Altoida: Digital cognitive assessment platform using smartphone-based tests and AI to detect early signs of cognitive impairment. Emerging peer — overlaps with BrainHealth Clinic's cognitive-assessment and longitudinal-care functionality for neurodegenerative disease.
- Neurotrack Technologies: Digital health company offering cognitive assessment and longitudinal brain-health monitoring tools. Emerging peer — competes in the digital cognitive-evaluation layer adjacent to BrainHealth Clinic.
- Cognito Therapeutics: Digital therapeutics and brain-stimulation company developing disease-modifying therapies for Alzheimer's and neurodegeneration. Emerging peer — overlaps with NeuroVision's longitudinal cognitive-care platform and shares pharma-partner distribution channels.
Broad incumbents
- Roche Diagnostics: Global diagnostics incumbent offering Elecsys amyloid and pTau-217 blood assays for Alzheimer's disease on the cobas platform. Broad incumbent — overlapping capability with NeuroVision's blood-biomarker franchise but at much greater scale and regulatory maturity.
- Labcorp: National clinical laboratory network with Alzheimer's and neurodegenerative-diagnostic test menu (and a NeuroVision strategic investor). Broad incumbent — both a potential distribution channel and an indirect competitor in commercial blood-biomarker testing.
- Quest Diagnostics: National clinical laboratory offering AD-detect blood-based biomarker tests and neurology diagnostics. Broad incumbent — comparable scale and reference-lab positioning to NeuroVision's enterprise distribution ambitions in cognitive diagnostics.
- Biogen: Large biotech commercializing Leqembi (lecanemab) for early Alzheimer's disease. Broad incumbent — not a diagnostic competitor per se, but a critical customer/partner driving demand for early-detection infrastructure like NeuroVision's.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
NeuroVision Imaging social profiles
Digital presenceNeuroVision Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroVision Imaging leadership team
Management profileNumber of profiles
Profiles11 records
NeuroVision Imaging subsidiaries and ownership
Company hierarchySubsidiaries1 record
NeuroVision Imaging funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroVision Imaging M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroVision Imaging
What does NeuroVision Imaging do?
NeuroVision Imaging develops and operates an integrated multi-modal diagnostic platform for neurodegenerative diseases, combining cloud-based AI retinal imaging (Afina™), blood-based autoantibody biomarker diagnostics (Duritect™), and a national telehealth cognitive care delivery platform (BrainHealth Clinic™ / BrainHealth.net). The platform connects primary care identification, biomarker interpretation, neurology consultation, and longitudinal patient management across the cognitive care journey.
Is NeuroVision Imaging a public or private company?
NeuroVision Imaging is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeuroVision Imaging founded?
NeuroVision Imaging was founded in 2010. It employs 1 to 10 people.
Where is NeuroVision Imaging based?
NeuroVision Imaging is headquartered in Sacramento, United States, in the North America region.
How does NeuroVision Imaging make money?
Three revenue lines are on record. Telehealth Cognitive Care Services are the primary driver. The others are diagnostic Testing (Afina retinal imaging & Duritect blood biomarkers) and enterprise / Health System Partnerships.
Who are NeuroVision Imaging's main competitors?
Direct peers on record are C2N Diagnostics, RetiSpec and Quanterix. Emerging players are Altoida, Neurotrack Technologies and Cognito Therapeutics. Broad incumbents are Roche Diagnostics, Labcorp, Quest Diagnostics and Biogen.
Does NeuroVision Imaging have an API?
No public API is recorded for NeuroVision Imaging.
What industry is NeuroVision Imaging in?
NeuroVision Imaging's product category is Neurodegenerative Disease Diagnostics. Its primary akta.pro industry code is HLALAGAC, Neurology Telemedicine Platforms, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3845.